To preliminarily investigate the clinical efficacy of CTLA4Ig gene-transfected porcine skin combined with de-epidermized dermal tissue homogenate in the treatment of deep burn wounds.

A retrospective analysis was conducted on 28 patients with deep burns admitted to the Department of Burns and Wound Repair， Dongguan Houjie Hospital from June 2023 to June 2025. There were 22 males and 6 females， aged 21–67 years， with a mean age of （44.61±12.29） years. Patients were divided into the observation group （15 cases） and the control group （13 cases） according to the treatment protocol. The observation group received autologous de-epidermized dermis homogenate combined with CTLA4Ig gene-transfected porcine skin transplantation， while the control group received CTLA4Ig gene-transfected porcine skin transplantation alone. Wound healing time， postoperative inflammatory factor levels， and scar hyperplasia were compared between the two groups. Scar quality was evaluated using the Vancouver scar scale （VSS）， including scores for pigmentation， thickness， vascularity， and flexibility， with total score calculated. Adverse events during treatment were recorded.

Complete wound healing time was significantly shorter in the observation group than in the control group ［（20.07±2.49） d vs. （26.92±6.49） d， P<0.001］. Interleukin-6 （IL-6） levels at 1 and 7 days postoperatively were significantly lower in the observation group （all P<0.05）. At 3 months postoperatively， the VSS score was significantly lower in the observation group ［（4.53±1.06） vs. （5.62±1.50）， P<0.05］.

De-epidermized dermis homogenate combined with CTLA4Ig gene-transfected porcine skin can significantly shorten wound healing time， reduce postoperative inflammatory response， and effectively improve scar quality， providing a novel combined repair strategy for the treatment of deep burn wounds.